Provided by Tiger Trade Technology Pte. Ltd.

Voyager Therapeutics

3.40
+0.00500.15%
Volume:194.39K
Turnover:651.72K
Market Cap:209.19M
PE:-1.87
High:3.41
Open:3.39
Low:3.24
Close:3.39
52wk High:5.55
52wk Low:2.94
Shares:61.62M
Float Shares:44.40M
Volume Ratio:0.53
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8121
EPS(LYR):-2.0400
ROE:-54.09%
ROA:-27.34%
PB:1.36
PE(LYR):-1.66

Loading ...

Voyager Therapeutics Wins FDA IND Clearance for Alzheimer’s Gene Therapy Vy1706

Reuters
·
Jun 29

H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)

TIPRANKS
·
Jun 25

Voyager Therapeutics CEO to present fireside chat at H.C. Wainwright Neuro Perspectives conference webcast

Reuters
·
Jun 12

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

TIPRANKS
·
Jun 11

Voyager Therapeutics shareholders approve authorized share increase at annual meeting

Reuters
·
Jun 11

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)

TIPRANKS
·
Jun 09

Guggenheim Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)

TIPRANKS
·
Jun 02

Voyager Therapeutics announces FDA clearance for VY1706 IND application

TIPRANKS
·
Jun 01

Voyager Therapeutics says FDA clears IND for Alzheimer’s gene therapy VY1706

Reuters
·
Jun 01

Voyager Receives FDA Ind Clearance for Vy1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

THOMSON REUTERS
·
Jun 01

Voyager Therapeutics - to Initiate Vy1706 Clinical Trial in Adults With Early Alzheimer's; Dosing Expected H2 2026

THOMSON REUTERS
·
Jun 01

Voyager Therapeutics’ Amy Quinlan, principal accounting officer, files initial beneficial ownership statement

Reuters
·
May 19

Analysts’ Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), Voyager Therapeutics (VYGR)

TIPRANKS
·
May 18

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Climb Bio (CLYM)

TIPRANKS
·
May 15

Voyager Asgct Late Breaker: Single Iv Dose of Vy1706 Well Tolerated, Reduced Tau in 3-Month Glp Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

THOMSON REUTERS
·
May 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 11

Canaccord Genuity Remains a Buy on Voyager Therapeutics (VYGR)

TIPRANKS
·
May 11

Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings

TIPRANKS
·
May 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (VYGR), Alpha Teknova (TKNO) and RxSight (RXST)

TIPRANKS
·
May 09

Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)

TIPRANKS
·
May 08